Professional Documents
Culture Documents
net/publication/6781766
CITATIONS READS
112 487
2 authors:
Some of the authors of this publication are also working on these related projects:
Project 1. Clinical development of novel pharmacotherapeutics for autism spectrum disorders. Project 2. Clinical development of novel pharmacotherapeutics for major
depressive disorder. View project
All content following this page was uploaded by Eric Hollander on 10 August 2014.
T he article in this issue by Koran et al. raises several intriguing questions regarding a
novel proposed psychiatric disorder: compulsive buying. DSM provides a working
model of categories and diagnostic criteria for psychiatric disorders. DSM is constantly
evolving and research planning is underway for DSM-V. Changes to DSM-V being con-
sidered include the creation of two broad new categories that may influence the con-
ceptualization of compulsive buying.
A category related to obsessive-compulsive-related disorders might include disorders
such as obsessive compulsive disorder, obsessive compulsive personality disorder,
hoarding, body dysmorphic disorder, eating disorders, hypochondriasis, Tourette’s syn-
drome, Sydenham’s chorea or pediatric autoim-
mune neuropsychiatric disorders associated
“Changes to DSM-V being with streptococcal infections, and pathological
considered include the grooming disorders, such as trichotillomania,
skin picking, and nail biting. Compulsive buying
creation of two broad was not determined to be a good fit for this cate-
new categories that gory. On the other hand, a parallel category un-
may influence the der consideration is behavioral and substance
addictions, which might include substance-re-
conceptualization of lated disorders and several impulse-control dis-
compulsive buying.” orders (pathological gambling, pyromania, and
kleptomania), as well as others currently in the
category of impulse control disorders not other-
wise specified (Internet addiction, impulsive-compulsive sexual behavior, and compul-
sive buying). The National Institute on Drug Abuse has considered behavioral addic-
tions (such as compulsive buying) to be “cleaner” and more homogeneous models of
substance addictions because these conditions may share clinical features and perhaps
underlying brain circuitry, and these features and circuitry are not altered by the inges-
tion of exogenous substances. Similar phases seem to occur for behavioral and sub-
stance addictions: initially, episodes are characterized by increasing physiological and
emotional arousal before the act; pleasure, high, or gratification associated with the act;
and a decrease in arousal and feelings of guilt and remorse afterward. Tolerance and
physiological withdrawal can also develop. Because an impulsive component (pleasure,
arousal, or gratification) is involved in initiating the cycle, and a compulsive component
is involved in the persistence of the behavior, these conditions may also be thought of
as impulsive-compulsive disorders.
The creation of a condition such as compulsive buying might be associated with con-
troversy and criticized by some as creating a trivial disorder; “medicalizing” a “moral”
problem or creating a new disorder in order to sell more pharmaceuticals. Similar criti-
cisms of attention deficit hyperactivity disorder (ADHD) and social anxiety disorder
have been raised: that children with minor and natural levels of excess activity should
not be “medicalized” or medicated or that because so many people are socially anxious,
this is a natural trait not worthy of diagnosis or treatment. However, the issues involved
in creating new diagnoses is complex.
In this issue, Koran et al. reported on a study of compulsive buying. They surveyed a
large random sample of U.S. adults to estimate a prevalence rate and to characterize
compulsive buyers. They and others have proposed names and diagnostic criteria for
this problem and, as required for most DSM disorders, the criteria include significant
Reference
1. Faber RJ, O’Guinn TC: A clinical screener for compulsive buying. J Consumer Res 1992; 19:459–469
Address correspondence and reprint requests to Dr. Hollander, Department of Psychiatry, Mt. Sinai School of
Medicine, One Gustave L Levy Place, New York, NY 10029; eric.hollander@mssm.edu (e-mail.)
Dr. Hollander has been a consultant to Ortho-McNeil, Abbott, and Forest; and has received research grants
from NIMH, NIDA, NINDS, and OPD-FDA. Dr. Freedman has reviewed this editorial and found no evidence of
influence from these relationships. Dr. Allen reports no competing interests.